Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
FDA Fast-Track Drug Reviews Delayed Over Safety and Efficacy Concerns 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Chime Forecasts Strong 2026 Revenue Growth, Shares Jump on Profit Outlook 
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing 
OpenAI Hires Former Meta and Apple AI Leader Ruomin Pang Amid Intensifying AI Talent War 
Flare, Xaman Roll Out One-Click DeFi Vault for XRP Yield via XRPL Wallets 
FAA Plans Flight Reductions at Chicago O’Hare as Airlines Ramp Up Summer Schedules 
Netflix Declines to Raise Bid for Warner Bros. Discovery Amid Competing Paramount Skydance Offer 
FCC Approves Charter Communications’ $34.5 Billion Acquisition of Cox Communications 
Synopsys Q2 Revenue Forecast Misses Expectations Amid China Export Curbs and AI Shift 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Trump Orders Federal Agencies to Halt Use of Anthropic AI Technology 
Packaged food manufacturers and fast-food restaurants are preparing for major shifts in consumer demand as appetite-suppressing GLP-1 weight loss pills are expected to enter the U.S. market in early 2025. Analysts believe these oral medications could accelerate long-term changes in eating habits, forcing food companies to reformulate products, adjust portion sizes, and emphasize nutrition-focused offerings.
The U.S. Food and Drug Administration recently approved Novo Nordisk’s Wegovy GLP-1 pill, a milestone that sent shares of several food companies lower. Unlike injectable GLP-1 drugs, the pill form is expected to be cheaper and more appealing to patients who are uncomfortable with injections. Eli Lilly’s competing GLP-1 pill is also anticipated to receive regulatory approval next year, further expanding access to weight loss medications.
As adoption grows, analysts say Americans are likely to reduce consumption of calorie-dense foods such as salty snacks, baked goods, soda, alcohol, and sugary drinks. Instead, demand is shifting toward high-protein, high-fiber, and functional foods that support satiety and portion control. This trend has already been visible with injectable GLP-1 drugs and is expected to intensify with easier-to-use pills.
Research supports this shift. A recent Cornell University study found that households using GLP-1 medications reduced grocery spending by over 5% and fast-food spending by about 8%. While spending rebounded after discontinuing the drugs, experts believe lower-cost pills could encourage longer-term use, broadening the impact across the food industry.
Major companies are responding quickly. Conagra Brands has begun labeling certain Healthy Choice meals as “GLP-1 friendly,” citing faster sales than competing products. Danone reports double-digit growth in high-protein yogurt, while Nestlé has launched new frozen meals tailored to GLP-1 users. Restaurants are also adapting, with chains like Chipotle introducing high-protein menu options and others offering smaller, lower-priced portions.
With nearly 40% of U.S. adults classified as obese and growing interest in weight loss solutions, GLP-1 pills are poised to reshape how Americans eat—and how food companies innovate—for years to come.
